Your browser doesn't support javascript.
loading
Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease / 生理学报
Acta Physiologica Sinica ; (6): 682-690, 2023.
Article in Zh | WPRIM | ID: wpr-1007783
Responsible library: WPRO
ABSTRACT
Metabolic associated fatty liver disease (MAFLD) is a liver disease with hepatocyte steatosis caused by metabolic disorders, which is closely related to obesity, diabetes, metabolic dysfunction, and other factors. Its pathological process changes from simple steatosis, liver inflammation to non-alcoholic steatohepatitis (NASH), and then leads to liver fibrosis, cirrhosis, and liver cancer. At present, no specific therapeutics are available for treatment of MAFLD targeting its etiology. Celastrol is the main active component of the traditional Chinese medicine Celastrus orbiculatus Thunb. In recent years, it has been found that celastrol shows important medicinal value in regulating lipid metabolism, reducing fat and weight, and protecting liver, and then ameliorates MAFLD. This article reviews the related research progress of celastrol in the prevention and treatment of MAFLD, so as to provide a reference for the comprehensive development and utilization of celastrol.
Subject(s)
Full text: 1 Database: WPRIM Main subject: Pentacyclic Triterpenes / Non-alcoholic Fatty Liver Disease / Liver / Obesity Limits: Humans Language: Zh Journal: Acta Physiologica Sinica Year: 2023 Document type: Article
Full text: 1 Database: WPRIM Main subject: Pentacyclic Triterpenes / Non-alcoholic Fatty Liver Disease / Liver / Obesity Limits: Humans Language: Zh Journal: Acta Physiologica Sinica Year: 2023 Document type: Article